Imatinib mesylate in children and adolescents with cancer

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Pediatric Blood & Cancer

• Publication date

  2010-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pbc.22484PMID 20486169
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute Lymphoblastic Leukemia in Children and Adolescents

  2018cited by this paper
• Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).

  2010cited by this paper
• Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

  2010cited by this paper
• Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate

  2010cited by this paper
• Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP)

  2010cited by this paper
• Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

  2010cited by this paper
• Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment.

  2010cited by this paper
• Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.

  2010cited by this paper
• Dysregulation of bone remodeling by imatinib mesylate.

  2010cited by this paper
• Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.

  2009cited by this paper
• Imatinib for refractory chronic graft-versus-host disease with fibrotic features.

  2009cited by this paper
• Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

  2009cited by this paper
• Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.

  2009cited by this paper
• Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

  2009cited by this paper
• Current treatment options in dermatofibrosarcoma protuberans

  2009cited by this paper
• Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

  2009cited by this paper
• Imatinib mesylate causes growth plate closure in vivo

  2009cited by this paper
• Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib

  2009cited by this paper
• Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib

  2009cited by this paper
• Neoadjuvant imatinib therapy for dermatofibrosarcoma protuberans.

  2009cited by this paper
• Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population

  2009cited by this paper
• Growth deceleration in a girl treated with imatinib

  2009cited by this paper
• Hits and misses in targeting pediatric cancers

  2009cited by this paper
• TG-0054, a Novel and Potent Stem Cell Mobilizer, Displays Excellent PK/PD and Safety Profile in Phase I Trial.

  2009cited by this paper
• Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.

  2009cited by this paper
• The Immunophenotype Signature CD49d+CD38+ Identifies Chronic Lymphocytic Leukemia Cases with a Higher Potential for Migration Beneath Marrow Stromal Cells.

  2009cited by this paper
• Imatinib Is Efficient but Has a Negative Impact On Growth in Children with Previously Untreated chronic Myelogenous Leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial.

  2009cited by this paper
• Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

  2009cited by this paper
• Imatinib Mesylate Induced Cardiotoxicity: a Cardiac Progenitor Cell Disease?.

  2009cited by this paper
• Hypophosphatemia During Imatinib Treatment of Newly Diagnosed Chronic Myeloid Leukemia Patients Is Associated with Better Response.

  2009cited by this paper
• Imatinib as Salvage Therapy for Patients with Refractory cGVHD: the Interim Analysis of the Prospective GITMO* Multicenter Study*Gruppo Italiano Trapianto Di Midollo Osseo.

  2009influential reference
• Chronic Myeloid Leukemia in Pediatrics — First Results From Study CML-PAED II.

  2009cited by this paper
• Discontinuation of Imatinib Therapy After Achieving a Molecular Response in Chronic Myeloid Leukemia Patients.

  2009cited by this paper
• Chronic Eosinophilic Leukaemia (CEL) with FIP1L1-PDGFRalpha Rearrangement (F/P): The Response to Imatinib (IM) Is Durable. A Report of 33 Patients with A Follow –up of 30 to 92 Months.

  2009cited by this paper
• CD14+ hla-DR-/Lo Myeloid-Derived Suppressor Cells Express Immunosuppressive B7-H Family Members and Are Depleted Following Taxane-Based Chemotherapy in Melanoma.

  2009cited by this paper
• The Role of β2-Glycoprotein I in the Clearance of Platelet Microvesicles.

  2009cited by this paper
• Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients.

  2009cited by this paper
• Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV.

  2009cited by this paper
• Targeted Lymphocyte Depletion Prior to Reduced Intensity Allogeneic Stem Cell Transplantation: A Personalized Approach to Facilitate Engraftment.

  2009cited by this paper
• Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients.

  2009cited by this paper
• High Complete and Very Good Partial Response Rates with Bortezomib—Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial.

  2009cited by this paper
• Dasatinib Is Well-Tolerated and Efficacious in Imatinib-Intolerant Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML).

  2009cited by this paper
• Ectopic Expression and Role of RCAN1 in Myeloid Leukemia Cells.

  2009cited by this paper
• In Vitro Expanded NK Cells Have Increased Natural Cytotoxity Receptors, TRAIL and NKG2D Expression, and Superior Tumor Cytotoxicity Compared to Short-Term IL-2 –Activated NK Cells.

  2009cited by this paper
• Developmentally Restricted Protection From Notch1-Induced T Cell Acute Lymphoblastic Leukemia by the Arf Tumor Suppressor.

  2009cited by this paper
• Allogeneic Stem Cell Transplantation for Pediatric and Adolescent Patients with CML: Results from the Prospective Trial CML-paed I

  2009cited by this paper
• In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta.

  2009cited by this paper
• A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.

  2009cited by this paper
• The Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States.

  2009cited by this paper
• Systemic Administration of Pleiotrophin Induces Hematopoietic Stem Cell Regeneration In Vivo.

  2009cited by this paper
• The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS.

  2009cited by this paper
• Benefits of global partnerships to facilitate access to medicines in developing countries: a multi-country analysis of patients and patient outcomes in GIPAP

  2009cited by this paper
• Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation.

  2008cited by this paper
• Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.

  2008cited by this paper
• Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

  2008cited by this paper
• Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty.

  2008cited by this paper
• Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience from a developing country

  2008cited by this paper
• Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?

  2008cited by this paper
• Platelet‐derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma

  2008cited by this paper
• Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia

  2008cited by this paper
• Long-term imatinib therapy promotes bone formation in CML patients.

  2008influential reference
• Molecular Characterization of Pediatric Gastrointestinal Stromal Tumors

  2008cited by this paper
• Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

  2008cited by this paper
• A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study

  2008influential reference
• Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults

  2008cited by this paper
• Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults

  2008cited by this paper
• Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.

  2007cited by this paper
• Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.

  2007cited by this paper
• Chronic myeloid leukaemia.

  2007cited by this paper
• Treatment of chronic myeloid leukemia in the imatinib era

  2007cited by this paper
• Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors.

  2007cited by this paper
• Osteopenia and cancer in children and adolescents

  2007cited by this paper
• Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.

  2007cited by this paper
• KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.

  2006cited by this paper
• Imatinib mesylate in the treatment of systemic mastocytosis

  2006cited by this paper
• Leukaemia incidence and survival in children and adolescents in Europe during 1978-1997. Report from the Automated Childhood Cancer Information System project.

  2006cited by this paper
• Altered bone and mineral metabolism in patients receiving imatinib mesylate.

  2006cited by this paper
• Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

  2006cited by this paper
• Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation

  2006cited by this paper
• Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior

  2006cited by this paper
• Insulin-Like Growth Factor I Receptor Pathway Inhibition by ADW742, Alone or in Combination with Imatinib, Doxorubicin, or Vincristine, Is a Novel Therapeutic Approach in Ewing Tumor

  2006cited by this paper
• Imatinib mesylate: An attractive alternative in young children with large, surgically challenging dermatofibrosarcoma protuberans

  2005cited by this paper
• Gastrointestinal Stromal Tumors of the Stomach in Children and Young Adults: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 44 Cases With Long-Term Follow-Up and Review of the Literature

  2005cited by this paper
• METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS

  2005cited by this paper
• Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.

  2005cited by this paper
• Gastrointestinal Stromal Tumors in Children and Young Adults: A Clinicopathologic, Molecular, and Genomic Study of 15 Cases and Review of the Literature

  2005cited by this paper
• Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia

  2005cited by this paper
• Therapy of chronic myeloid leukemia with imatinib mesylate in Brazil: a study of 98 cases

  2005cited by this paper
• Molecular genetics of acute lymphoblastic leukemia.

  2005cited by this paper
• PDGF-A, PDGF-Rβ, TGFβ3 and bone morphogenic protein-4 in desmoplastic small round cell tumors with EWS-WT1 gene fusion product and their role in stromal desmoplasia: an immunohistochemical study

  2005cited by this paper
• Imatinib Inhibits Proliferation of Ewing Tumor Cells Mediated by the Stem Cell Factor/KIT Receptor Pathway, and Sensitizes Cells to Vincristine and Doxorubicin-Induced Apoptosis

  2004cited by this paper
• Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

  2004cited by this paper
• Imatinib mesylate ( STI 571 ) for treatment of children with Philadelphia chromosome – positive leukemia : results from a Children ’ s Oncology Group phase 1 study

  2004cited by this paper
• Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.

  2004cited by this paper
• Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study.

  2004cited by this paper
• Imatinib mesylate in the treatment of systemic mastocytosis, a phase I/II trial

  2004cited by this paper
• CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid

  2004cited by this paper
• Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro

  2004cited by this paper
• Pediatr Blood Cancer

  2004cited by this paper
• Expression of Ligand-Activated KIT and Platelet-Derived Growth Factor Receptor β Tyrosine Kinase Receptors in Synovial Sarcoma

  2004cited by this paper

• Multi-tyrosine kinase inhibitors in paediatric soft tissue sarcoma – A review

  2026cites this paper
• Impact of Tyrosine Kinase Inhibitors (TKIs) on Growth in Children and Adolescents with Chronic Myeloid Leukemia: A Systematic Review.

  2024cites this paper
• Experience of the Spanish Group for Hematopoietic Transplantation (GETMON-GETH) in allogenic Hematopoietic stem cell Transplantation in Philadelphia acute lymphoblastic leukemia.

  2022cites this paper
• [Experience of the Spanish Group for Hematopoietic Transplantation (GETMON-GETH) in allogenic hematopoietic stem cell transplantation in Philadelphia acute lymphoblastic leukemia].

  2021cites this paper
• Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics

  2020cites this paper
• Pharmacotherapy in Children and Adolescents: Oncology.

  2019cites this paper
• Pharmacology and pharmacokinetics of imatinib in pediatric patients

  2018cites this paper
• Locoregional cancer therapy using polymer-based drug depots.

  2016cites this paper
• Wildtype ′ gastrointestinal stromal tumors

  2016cites this paper
• Novel approaches to pediatric leukemia treatment

  2015cites this paper
• Polymeric particles for sustained and local drug delivery

  2015cites this paper
• Dermatofibrosarcoma Protuberans: an Update and Review

  2015cites this paper
• Current Concepts in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

  2014cites this paper
• Imatinib inhibits the expression of SCO2 and FRATAXIN genes that encode mitochondrial proteins in human Bcr-Abl⁺ leukemia cells.

  2014cites this paper
• Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF‐1 axis

  2013cites this paper
• Anti-Angiogenic Effects of Diltiazem , Imatinib , and Bevacizumab in the CAM Assay

  2013cites this paper
• Successful Treatment of Pansclerotic Morphea with Imatinib Mesylate in a Pediatric Patient

  2013influential citation
• Targeted Drug Discovery for Pediatric Leukemia

  2013influential citation
• Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.

  2013cites this paper
• Imatinib mesylate in the treatment of diffuse cutaneous mastocytosis.

  2013cites this paper
• Future of clinical genomics in pediatric oncology.

  2013cites this paper
• Pediatr Blood Cancer 2013 ; 60 : 889 – 891 Essential Medicines for Pediatric Oncology in Developing Countries

  2013cites this paper
• Targeted Therapeutics in Treatment of Children and Young Adults with Solid Tumors: an Expert Survey and Review of the Literature

  2012cites this paper
• Pediatric gastrointestinal stromal tumor.

  2012cites this paper
• Chronic Myeloid Leukemia (CML) in Children: Classical and Newer Therapeutic Approaches

  2012cites this paper
• Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment

  2012cites this paper
• Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia

  2012cites this paper
• An update on leukaemia

  2012cites this paper
• Hémato-oncologie pédiatrique : de la biologie cellulaire aux traitements ciblés et individualisés

  2012cites this paper
• Treatment of Pediatric Acute Lymphoblastic Leukemia and Recent Advances

  2011cites this paper
• [Indications and current development of new targeted therapies in pediatric oncology].

  2011cites this paper
• Intermediate dose of imatinib in combination with chemotherapy followed by allogeneic stem cell transplantation improves early outcome in paediatric Philadelphia chromosome‐positive acute lymphoblastic leukaemia (ALL): results of the Spanish Cooperative Group SHOP studies ALL‐94, ALL‐99 and ALL‐2005

  2011cites this paper
• Controversies in the treatment of CML in children and adolescents: TKIs versus BMT?

  2011cites this paper
• Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia.

  2011cites this paper
• Pediatric gastrointestinal stromal tumors.

  2009cites this paper